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Abstract Sickle cell anemia (SCA) is characterized by a
marked endothelial dysfunction, owing to many factors.
Arginine metabolism can be related to the inflammatory
chronic state presented by patients, playing a key role in
their clinical outcome and vascular endothelium. We
investigated the serum arginase levels in 50 SCA patients
(22 men and 28 women, mean age of 17±10.5 years) and
28 healthy controls. Serum arginase levels were associated
with biochemical hemolysis markers and cytokines in-
volved in Th17 response, as well as levels of soluble
intercellular adhesion molecule-1 (sICAM-1) and vascular
cell adhesion molecule-1 (sVCAM-1). Arginase concen-
trations were higher in SCA patients, compared with
controls (p=0.005), and were significantly and positively
associated with total bilirubin (p=0.004), indirect bilirubin
(p=0.04), and aspartate aminotransferase (AST; p=0.039)
in the SCA patient group. Moreover, arginase was
significantly and positively associated with transforming
growth factor-beta (TGF-beta; p=0.008) among SCA
patients. sICAM-1 was significantly and positively associ-
ated to reticulocytes (p=0.014) and AST (p=0.04).
sVCAM-1 was likewise associated with lactate dehydroge-
nase (p=0.03). These data suggest a new insight into
arginase metabolism, as we show here a shift in arginine
catabolism, where TGF-beta may induces the arginase
pathway instead of the nitric oxide pathway and a possible
involvement of the vascular activation and the serum
arginase in chronic hemolysis among SCA patients.
Additional studies should be carried out in order to
investigate the mechanisms by which TGF-beta participates
in the metabolism of arginase in SCA patients.
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Introduction
Sickle cell anemia (SCA) has been characterized by a
chronic inflammatory state, with the presence of elevated
leukocyte counts, abnormal activation of granulocytes,
monocytes and endothelial cells, and an increased level of
multiple inflammatory mediators. Cytokine expression may
play a role in the clinical outcome of SCA patients. Its
effects on vascular endothelium and adhesion molecule
expression have been considered relevant [1–3].
Normal arginine metabolism is impaired in SCA,
contributing to endothelial dysfunction and pulmonary
hypertension [4]. Arginase catalyzes the hydrolysis of L-
arginine into L-ornithine and urea. It is widely distributed in
living organisms, utilizing arginine as its substrate [5]. In
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intravascular hemolysis contributes to endothelial dysfunc-
tion, which has been characterized by a reduction in nitric
oxide (NO) bioavailability and NO resistance [6]. Given the
important role of NO depletion in endothelial dysfunction,
it is not surprising that NO dysregulation is a common
finding among the varied mechanisms involved in sickle
vasculopathy [7]. Arginasecan be inducedinmanycelltypes
by a variety of cytokines and inflammatory stimuli [8, 9].
Interleukin 17 (IL-17) is an essential proinflammatory T-
cell-derived cytokine with several biological actions. It has
been found to play a pivotal role in microbial host defense
by interconnecting lymphoid and myeloid host defenses
[10]. While previously considered to be dependent on
interleukin-23 (IL-23) for differentiation from naive T cells
into Th17 cells, recent work has indicated that initial
differentiation is dependent on transforming growth factor-
beta (TGF-beta), with subsequent expansion of the Th17
lineage dependent on IL-23 [11]. The role of the Th17
response in vascular alterations has not been established.
Taleb et al. [12] showed that in vivo administration of IL-17
reduces endothelial vascular cell adhesion molecule-1
(VCAM-1) expression and vascular T-cell infiltration, and
significantly limits the development of atherosclerotic
lesions. However, Eid et al. [13] showed that IL-17 is
produced concomitantly with interferon gamma (IFN-
gamma) by coronary-artery-infiltrating T cells, which act
synergistically to induce proinflammatory responses in
vascular smooth muscle cells.
In macrophages, arginase gene expression is tightly
regulated by many factors, including exogenous stimuli
like the Th2 cytokines [14]. TGF-beta reduces the inducible
NO synthase activity of rat macrophage cultures, not only
down-regulating the inducible nitric oxide synthase path-
way, but also up-regulating the arginase pathway [15].
In this study we tested the hypothesis that serum
arginase concentration is influenced by some factors such
as hemolysis, and Th17 responses and is related to
endothelial dysfunction. We have tested that by evaluating
hemolysis markers as bilirubin, lactate dehydrogenase
(LDH) and aminotransferase, as well as cytokines involved
in the Th17 response (IL-23, IL-17, and TGF-beta) and
soluble adhesion molecules levels [soluble intercellular
adhesion molecule-1 (sICAM-1) and vascular cell adhesion
molecule-1 (sVCAM-1)].
Patients and methods
Subjects
We studied 50 patients (22 men and 28 women, mean age
of 17±10.5 years) from Northeast Brazil who were
diagnosed with SCA (HBSS) and were located at the
Foundation of Hematology and Hemotheraphy (HEMOBA)
in Bahia, Brazil. All patients were at a steady state and were
transfusion free. Patients showed no other systemic diseases
that could have potentially altered their inflammatory
profile functions. Blood samples were obtained during
regular clinical visits. Twenty-eight healthy Brazilian
subjects with normal hemoglobin profiles were included
as a control group. The study was approved by the Oswaldo
Cruz Foundation’s Human Research Board and is in
accordance with the Declaration of Helsinki of 1975, as
revised in 2000. All subjects signed an informed consent
form.
Biochemical analyses and serum arginase level
measurements
Serum concentrations of bilirubin, LDH, aspartate amino-
transferase (AST), and alanine aminotransferase (ALT)
were determined using commercially available biochemical
kits (LABTEST, Minas Gerais, Brazil). Arginase serum
levels in SCA patients and control groups were measured
using a Human Arginase I ELISA Kit (Cell science,
Canton, MA, USA) according to the manufacturer's
recommendations.
Cytokine and soluble adhesion molecule measurements
IL-23, IL-17, and TGF-beta were measured using Cytokine
ELISA OptEIA kits (BD Pharmingen, San Diego, CA,
USA) and soluble adhesion molecules were characterized
using ELISA Kits (R&D Systems, Minneapolis, MN,
USA), according to the manufacturer's recommendations.
Statistical analysis
Baseline characteristics were summarized as means and
proportions of selected variables. The distribution of
quantitative variables was determined using the Kolmo-
gorov–Smirnov test. Mean values of quantitative variables
between groups were compared using the unpaired t test for
normal data distribution and Mann–Whitney for non-
normal data. The Kruskal–Wallis test or ANOVA with
Bonferoni were used to compare means among two or more
groups, as measured by interval variables. Bivariate
correlation analyses were carried out to determine correla-
tions between pairs of variables using Pearson’sa n d
Spearman’s rank correlations (r). Linear regression analyses
were also performed. All tests were considered significant if
p values were less than 0.05. Data analyses were performed
using Prism 5.01 (Graphpad Software, San Diego, CA,
USA), EPIinfo 6.04 (CDC, Atlanta, Georgia, USA), and
STATA SE 10 software (StataCorp, Texas, USA).
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Arginase levels were higher in SCA patient sera compared
to controls
Serum arginase levels were quantified to determine the
amount of arginase released into the blood. Arginase serum
levels in SCA patients showed a twofold increase in
enzyme levels, compared with control patients (median
21.1 and 14.7 ng/mL, respectively). This was found to be
statistically significant (p=0.005; Fig. 1). Table 1 shows the
hematologic and hemolysis markers values of the SCA
patients group.
Correlation of arginase levels and hemolytic biochemical
markers
The association between serum arginase concentrations and
clinical hemolysis laboratory markers was determined to
confirm the mechanisms that increase enzyme levels in
SCA patients. Serum arginase levels were positively and
significantly associated with total bilirubin (p=0.004, r=
0.397), indirect bilirubin (p=0.040, r=0.291), and AST (p=
0.024, r=0.320). Correlation analysis of AST showed a
positive association with LDH (p<0.001, r=0.59) and total
bilirubin (p<0.001, r=0.49).
Arginase was positively and significantly associated
with a high expression of TGF-beta among SCA patients
In this work, we investigated cytokines involved in Th17
response and arginase expression regulation (e.g., IL-23,
IL-17, and TGF-beta), associating these with free arginase
in SCA individuals. There was a positive and significant
association between arginase and TGF-beta (p=0.008, r=
0.588), as shown in Table 2. The linear regression of
arginase levels was also positively and significantly
associated with AST (p<0.0001, r=0.522), total bilirubin
(p=0.034, r=0.301), and indirect bilirubin (p=0.039, r=
0.293; Fig. 2).
Rises in hemolytic rate is correlated to sVCAM-1
and sICAM-1 expression
We also studied vascular and leukocyte activation using
sVCAM-1 and sICAM-1 serum level measurements. We
found a positive and significant correlation among sICAM-
Fig. 1 Arginase serum levels between sickle cell anemia patients and
control groups
Table 1 Steady-state hematologic and hemolysis markers values of
the SCA patients group
Median SD
Hematology values
RBC (×10
6/μL) 2.69 0.67
Hemoglobin (g/dL) 8.07 1.60
Hematocrit (%) 24.42 5.26
Platelets (×10
3/μL) 368 178
Reticulocytes count (%) 6.9 3.1
Hemolysis markers
Total bilirubin (mg/dL) 2.35 1.74
Direct bilirubin (mg/dL) 0.72 0.61
Indirect bilirubin (mg/dL) 1.64 1.35
AST (U/l) 44.55 29.96
ALT (U/l) 11.25 9.63
SD standard deviation, AST aspartate aminotransferase, ALT alanine
aminotransferase
Table 2 Correlation between arginase serum levels, TH17-related
cytokine, and soluble adhesion molecules levels in SCA patients
ARGINASE
Cytokine p value r
IL-23 0.459 0.181
IL-4 0.684 −0.100
IL-17 0.110 0.378
TGF-beta 0.008
a 0.588
Soluble adhesion molecules
sICAM-1 0.192 −0.313
sVCAM-1 0.303 0.249
aSpearman or Pearson correlation coefficient (r) and p values
sICAM-1 soluble intracellular adhesion molecule-1, sVCAM-1 soluble
vascular cell adhesion molecule-1, TGF-beta transforming growth
factor-beta
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with AST (p=0.04, r=0.227), which are both classical
hemolysis markers. Moreover, soluble VCAM-1 levels
were associated with an increase in LDH levels (p=0.041,
r=0.28). No association was found between arginase and
sVCAM-1 or sICAM-1 (Table 2).
Discussion
Results presented here demonstrate that free arginase levels
in the sera of SCA patients are markedly increased when
compared with healthy individuals. This is in agreement, in
part, with a previous report that estimated the rise in
arginase activity for SCA patients [4], while we have
investigated the enzyme concentration and not its activity.
A high concentration of free arginase in plasma is supposed
to deplete the circulating L-arginine. It is known that adults
with sickle cell disease are arginine deficient when in a
steady state, also, plasma arginine concentrations signifi-
cantly decrease in both adults and children during vaso-
occlusive crisis and acute chest syndrome, and this effect is
associated with low NO metabolite levels [16]. Clinical
trials with L-arginine supplementation appear to correct the
NO deficiency and ameliorate pulmonary hypertension. In
addition, red-cell adherence to the pulmonary endothelium
appears to decrease with increasing NO [17, 18].
During hemolysis, free hemoglobin is decompartmental-
ized from the erythrocyte and is released into plasma, where
it rapidly reacts with and destroys NO. This contributes to
an abnormally high NO consumption and the formation of
reactive oxygen species, ultimately inhibiting vasodilation.
NO destruction by free hemoglobin can also contribute to
impairment of vascular endothelial function via transcrip-
tional activation of adhesion molecules, including VCAM-1
and E-selectin, as well as potent vasoconstrictors such as
endothelin-1 [19]. Results presented here strongly suggest
that the major source of free serum arginase released into
plasma was the erythrocyte, as we found a positive
correlation between hemolytic biochemical markers and
arginase. Thus, a worsening in the clinical outcome can be
observed by the simultaneous release of erythrocyte
arginase during hemolysis, which will also limit the
availability of arginine to NOS, contributing to a NO
deficiency [4, 19]. In fact, this observation was supported
by results from sVCAM-1 and sICAM-1, which were
positively associated with hemolysis markers, such as AST,
LDH, and reticulocyte count.
Characterizing NO metabolism is an important goal in
SCA studies, as NO regulates blood vessel tone, endothelial
adhesion, leukocytes, and platelet activity. These are
important factors in ischemia-reperfusion injury and
sickle-cell-induced ischemia. In sickle cell anemia more
adhesion molecules are produced owing to a decreased
availability of NO [20]. As part of the biochemical
program that facilitates blood flow and maintains vascu-
lar homeostasis, NO normally suppresses the expression
of VCAM-1, ICAM-1, and E-selectin. In fact, the
impairment of NO bioavailability, which is associated
with endothelial dysfunction, results in the pathological
activation of endothelial cells to express adhesion
molecules [21], contributing to new vaso-occlusive events.
Morris et al. [4] showed an association between sVCAM-1
and arginase levels. NO acts as an anti-inflammatory
mediator, affecting endothelial cell function by preventing
leukocyte adhesion to the endothelium through the inhibi-
tion of adhesion molecule expression [22]. However, no
correlation was found between such molecules in our
results. This might be due to the clinical state of patients,
who were in a steady state of the disease, at the moment of
blood collection.
We also investigated the association of cytokines related
to Th17 response and the extent of arginase release into the
plasma. There is not much information concerning this
topic in literature, and it has not been presented in the
Fig. 2 Linear regression of arginase serum (ng/mL) and hemolysis
markers in sickle cell anemia patients
880 Ann Hematol (2010) 89:877–882context of SCA. Among the studied cytokines, there is
no association between IL-23 and IL-17 concentrations
with arginase levels. However, SCA individuals with
increased levels of TGF-beta had the highest levels of
serum arginase. This is an intriguing result, considering
that the NO metabolic pathway in murine macrophages
is a key defense element for various infectious diseases.
Also, its role in diverse settings of immunopathology
h a sb e e nf i r m l ye s t a b l i s h e d[ 23]. Arginase activity in
macrophages is exclusively up-regulated in association
with cytokines involved in the Th2 immune response,
i n c l u d i n gt h ec y t o k i n e sI L - 4a n dI L - 1 0[ 9, 24], as well as
IL-13 and TGF-beta [25]. TGF-beta has effects on cell
proliferation and apoptosis, as well as on the response to
tissue injury, infection, bone homeostasis, endothelial
growth, pulmonary fibrosis, inflammation, immune regu-
lation, and extracellular matrix synthesis [26]. Our work
reinforces the model that the arginase pathway is regulated
by TGF-beta. This is true not only for its immune response
role, as previously described, but also in other types of
tissue that are involved in arginase metabolism. Naive T-
cell differentiation into Th17 cells is driven initially by
TGF-beta [11]. The lack of association among arginase
and Th17-related cytokines may be due to a secondary
role that these cytokines can perform in arginine metab-
olism, mainly when patients are in a steady state of the
disease.
The clinical outcomes of SCA patients are a conse-
quence of several events and can also be influenced by
genetic diversity. With this respect, the reciprocal regulation
of the NOS/arginase pathway that results in a metabolic
shift in arginine utilization, a key endogenous substrate of
both enzymes, may represent an important target to
modulate clinical symptoms and a further therapeutic
approach for SCA patients.
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